Literature DB >> 9748569

A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing.

L H Connors1, T Ericsson, J Skare, L A Jones, W D Lewis, M Skinner.   

Abstract

Variant forms of the plasma protein transthyretin (TTR) are associated with the most frequently occurring type of familial systemic amyloidosis. Organ system involvement in transthyretin type amyloidosis (ATTR) is often similar to that which occurs in light chain amyloid disease (AL). The proper diagnosis of ATTR is important since treatment (liver transplantation) differs from that in AL (chemotherapy). We present a two-step test to screen sera for variant TTRs using non-denaturing gel electrophoresis performed in 7.5% acrylamide (PAGE) followed by isoelectric focusing (IEF) between pH 4.0 and 7.0 in 2.5 M urea. Serum samples from 110 patients with amyloidosis and their relatives were tested using this IEF technique and compared to genetic mutation results. Sera from patients with ATTR who underwent liver transplantation were also examined prior to and following surgery. IEF analysis showed the presence of both wild-type and variant TTR in 74 of the 110 serum samples tested. Genomic DNA from peripheral blood was used to identify TTR gene mutations in 77 of the 110 patients. Fifteen variants including Val122Ile, preponderant in the African-American population, could be demonstrated by IEF. The sensitivity of IEF was 96% (74/77) and the specificity was 100% (33/33). The predictive values for a positive or negative result were 100% (74/74) and 92% (33/36), respectively. There were no false-positive results and 4% (3/77) false-negative results. In sera from patients with ATTR who underwent liver transplantation, variant TTR was detected by IEF before, but not after, surgery. A simple, accurate, sensitive method is presented as a useful screening test for variant transthyretins associated with ATTR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748569     DOI: 10.1016/s0925-4439(98)00037-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Detection of transthyretin variants using immunoprecipitation and matrix-assisted laser desorption/ionization bioreactive probes: a clinical application of mass spectrometry.

Authors:  R Théberge; L H Connors; M Skinner; C E Costello
Journal:  J Am Soc Mass Spectrom       Date:  2000-02       Impact factor: 3.109

2.  Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis.

Authors:  Amareth Lim; Tatiana Prokaeva; Mark E McComb; Lawreen H Connors; Martha Skinner; Catherine E Costello
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

3.  Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Authors:  Andreia Biolo; Sujata Ramamurthy; Lawreen H Connors; Carl J O'Hara; Hans K Meier-Ewert; Pamela T Soo Hoo; Douglas B Sawyer; David C Seldin; David S Seldin; Flora Sam
Journal:  Circ Heart Fail       Date:  2008-10-14       Impact factor: 8.790

4.  Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.

Authors:  Komei Tanaka; Eric E Essick; Gheorghe Doros; Kahraman Tanriverdi; Lawreen H Connors; David C Seldin; Flora Sam
Journal:  J Am Heart Assoc       Date:  2013-03-12       Impact factor: 5.501

5.  Transthyretin and complex protein pattern in aqueous humor of patients with primary open-angle glaucoma.

Authors:  F H Grus; S C Joachim; S Sandmann; U Thiel; K Bruns; K J Lackner; N Pfeiffer
Journal:  Mol Vis       Date:  2008-08-04       Impact factor: 2.367

6.  Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities.

Authors:  Andrew Staron; Lawreen H Connors; Luke Zheng; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2020-11-10       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.